EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.

Saved in:
Bibliographic Details
Title: EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines.
Authors: Latarani M; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Pucci P; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., Eccleston M; Belgian Volition SPRL, Parc Scientifique Créalys, Namur, BE, Belgium.; ValiRx PLC, Medicity Nottingham, Nottingham, UK., Manzo M; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Gangadharannambiar P; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Fischetti I; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Alborelli I; Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland., Mongiardini V; Molecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy., Mahmood N; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Colombo MP; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Grimaldi B; Molecular Medicine Research Line, Fondazione Istituto Italiano di Tecnologia (IIT), Genoa, Italy., Rigas S; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK., Akamatsu S; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Hawkes C; Division of Biomedical and Life Sciences, Lancaster University, Lancaster, UK., Wang Y; Department of Experimental Therapeutics, BC Cancer/University of British Columbia, Vancouver, Canada., Jachetti E; Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Crea F; Cancer Research Group, School of Life Health and Chemical Sciences, The Open University UK, Milton Keynes, UK.
Source: Epigenomics [Epigenomics] 2025 Feb; Vol. 17 (3), pp. 145-154. Date of Electronic Publication: 2025 Jan 29.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101519720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-192X (Electronic) Linking ISSN: 1750192X NLM ISO Abbreviation: Epigenomics Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1750-192X
DOI:10.1080/17501911.2025.2453419